Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma. Issue 4 (27th August 2021)

• Record Type: Journal Article
• Authors: Greenman, Yona; Bronstein, Marcello D
• Is Part Of: European journal of endocrinology. Volume 185:Issue 4(2021)
• Page Start: D11
• Page End: D20
• Publication Date: 2021-08-27
• Subjects: Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/EJE-21-0344
• Languages: English
• ISSNs: 0804-4643

Abstract

Abstract: Non-functioning pituitary adenomas (NFPA) usually present with symptoms of mass effect. Thus, the first-line treatment generally consists of transsphenoidal surgery. Since these tumors are usually large and invasive, post-surgical tumor remnants are common. Active surveillance is the follow-up strategy adopted by most pituitary centers, although the prevalence of residual tumor growth may reach 50% in 5–10 years, often leading to repeat surgery, radiation therapy, or both. NFPA remain the only pituitary tumor type for which no medical therapy has been approved. In this debate, we consider the evidence in favor and against using cabergoline to treat progressing NFPA.